RXRX Share Price Performance
US$4.58
-2.40 (-34.38%)
63.3% undervalued intrinsic discount
US$12.49
Fair Value
Price US$4.58
Talos US$12.49
AnalystConsensusTarget US$6.33
AnalystHighTarget US$10.00
Fair ValueUS$12.49
Share Pricen/a
Recursion Pharmaceuticals, Inc. Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 156 Fair Values set on narratives written by author
RXRX Community Narratives
TA
Fair Value US$12.49 63.3% undervalued intrinsic discount
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
3users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$6.33 27.7% undervalued intrinsic discount
Advanced AI And ML Will Transform Biotech Drug Discovery
0users have liked this narrative
1users have commented on this narrative
122users have followed this narrative
AN
Fair Value US$10 54.2% undervalued intrinsic discount
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
Recursion Pharmaceuticals is currently at a critical inflection point. For years, the company was viewed as a "science project"—a high-tech platform promising to revolutionize drug discovery with AI.Read more
3users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
TA
US$12.49
63.3% undervalued intrinsic discount
Talos's Fair Value
Revenue
80% p.a.
Profit Margin
37%
Future PE
40x
Price in 2030
US$16.71
Advanced AI And ML Will Transform Biotech Drug Discovery
Key Takeaways Advanced AI-driven platforms and large proprietary datasets are enhancing R&D efficiency, competitive positioning, and attractiveness for pharmaceutical partnerships. Strategic focus on internal pipeline progression and industry digitization trends positions the company for sustainable revenue growth and long-term commercial upside.Read more
0users have liked this narrative
1users have commented on this narrative
122users have followed this narrative
AN
US$6.33
27.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
78.75% p.a.
Profit Margin
16.03%
Future PE
124.08x
Price in 2028
US$7.77
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
Key Takeaways Recursion's advanced AI-driven platforms and proprietary models position it for industry-leading speed, scale, and precision in drug discovery, enabling superior margins and accelerated R&D productivity. Strategic partnerships and innovation cycles establish Recursion as a key player in biopharma pipelines, increasing its attractiveness for major collaborations and potential acquisitions.Read more
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$10
54.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
84.22% p.a.
Profit Margin
14.17%
Future PE
113.84x
Price in 2028
US$12.23
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
Key Takeaways High R&D spending and lack of commercial assets expose the company to negative cash flow, dilution, and earnings risk. Regulatory uncertainty, revenue instability from partnerships, and increasing competition jeopardize growth, margins, and long-term market potential.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
52.7% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
16.47% p.a.
Profit Margin
16.25%
Future PE
117.8x
Price in 2028
US$3.67
Trending Discussion
Recently Updated Narratives
TA
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
Fair Value: US$12.49 63.3% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RXRX: New CEO Appointment Will Spark Stronger Margins And AI-Driven Momentum
Fair Value: US$6.33 27.7% undervalued intrinsic discount
122 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
Fair Value: US$3 52.7% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Recursion Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.37
- -1,152.35%
- -1,637.81%
- 2.0%
About RXRX
- Founded
- 2013
- Employees
- 800
- CEO
- WebsiteView website
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
